Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors by Kaneko, Yoshikatsu et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
ARTICLE
JEM © The Rockefeller University Press  $8.00
Vol. 203, No. 3,  March 20, 2006  789–797  www.jem.org/cgi/doi/10.1084/jem.20051900
789
It is now well-established that IgG antibodies 
mediate their eff  ector activities in vivo through 
their engagement of FcγRs (1). Mice that are 
defi  cient in activation FcγRs, by virtue of the 
targeted disruption of the common γ chain, are 
protected from the pathogenic eff  ects of cyto-
toxic antibodies and immune complexes in 
both passive and active models of infl  ammation 
(2–6). In contrast, disruption of the inhibitory 
Fc receptor, FcγRIIB, enhances the patho-
genic activity of IgG antibodies in many of 
these models (7–11). Although individual sub-
classes of IgG display diff  erent in vivo activities 
(12), it has been diffi   cult, until recently, to ac-
count for the hierarchy of these activities based 
on their interaction with the activation FcγRs 
I and III. With the identifi  cation of a third, 
γ chain–dependent, IgG activation FcγR, 
FcγRIV (13), which selectively binds to IgG2a 
and 2b with intermediate affi   nity (Kd = 10−7), 
a direct association between IgG subclass ac-
tivity and FcγR binding could be established 
(13, 14). This association is based on the re-
spective binding affi   nities for each subclass to 
its cognate   activation and inhibitory FcγR, 
thus resulting in a ratio of activation to inhibi-
tion that is predictive of the in vivo activity 
of an antibody (13, 14). Thus, IgG2a has an 
A/I ratio of 70 and IgG2b has an A/I ratio of 
7, whereas IgG1 has an A/I ratio of 0.1, which 
fi  ts with the hierarchy of activities of these sub-
classes in vivo such that IgG2a > IgG2b >> 
IgG1. However, these activities can be modi-
fi  ed by the relative expression levels of the ac-
tivation and inhibitory receptor on a specifi  c 
eff  ector cell, thus changing the avidity of an 
antibody-antigen complex for a specifi  c activa-
tion/inhibitory pair. Infl  ammatory  cytokines, 
such as IFNγ and C5a, up-regulate activation 
receptors, while down-regulating the inhibi-
tory receptor (15–17). In contrast, high dose 
intravenous γ-globulin (IVIG) has been shown 
to up-regulate the inhibitory receptor (18, 19). 
The net result of these responses is to change 
the thresholds required for eff  ector cell trigger-
ing and initiation of an infl  ammatory cascade 
at a given concentration of cytotoxic antibod-
ies or immune complexes. IgG antibodies that 
interact with their restricted, cognate FcRs 
  resulting in low A/I ratios are more sensitive to 
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these avidity considerations than antibodies which interact 
with FcR with high A/I ratios (13, 14).
To investigate the consequences of subclass affi   nity for 
specifi  c FcRs and the impact of Fc receptor modulation on 
IgG-mediated infl  ammation in an active model of infl  amma-
tion, we selected the murine nephrotoxic nephritis model. 
This model resembles human Goodpasture’s Disease (20–22) 
by virtue of its dependence on the targeting eff  ect of anti–
glomerular basement membrane (GBM) antibodies to direct 
immune complex deposition to the GBM and initiate an in-
fl  ammatory response. The introduction of heterologous rab-
bit or sheep anti-GBM antiserum (NTS) results in an acute, 
complement-dependent, transient phase of renal injury (day 
0–4) that is characterized by mildly elevated blood urea nitro-
gen (BUN) and proteinuria (21–24). The development of 
mouse anti–rabbit or –sheep antibodies in the later, autolo-
gous stage of this model (day 4–14) results in immune com-
plex deposition and frank glomerulonephritis with renal 
failure and death (21, 22, 25). This autologous phase has been 
shown to be FcγR dependent (25, 26); mice lacking the 
common γ chain are protected from renal failure and death. 
An accelerated model of nephrotoxic nephritis has been de-
veloped in which mice are presensitized to the heterologous 
anti-GBM serum by preimmunization with normal, heterol-
ogous serum at day −4, followed by introduction of the het-
erologous anti-GBM serum at day 0, thus initiating the 
autologous phase of disease concomitant with the introduc-
tion of the anti-GBM serum (25, 26). Renal disease is evi-
dent by day 4, with signifi  cant mortality by day 8 through an 
FcγR-dependent pathway.
We now report the contribution of specifi  c IgG subclasses 
and their cognate FcγRs to this accelerated autologous model 
of nephrotoxic nephritis and demonstrate the role of FcR 
modulation by IVIG in this active model of infl  ammation. 
The intrinsic FcγR affi   nities of IgG2b for the specifi  c activat-
ing (FcγRIV) and inhibitory (FcγRIIB) receptor pair deter-
mines the pathology observed, whereas the selective receptor 
modulation by IVIG of both of these molecules alters their 
ratio on the infi  ltrating eff  ector cells and contributes to the 
protection observed.
RESULTS
The nephrotoxic nephritis model
Presensitization of C57BL/6 mice with normal sheep IgG 
followed 4 d later by the introduction of sheep anti–mouse 
GBM serum induces acute glomerulonephritis with renal in-
jury, as seen in Fig. 1. Elevated BUN was observed by day 4 
in wild-type mice presensitized with normal sheep IgG and 
exposed to sheep NTS (CFA + NTS). Presensitization with 
sheep IgG alone, or exposure to anti-GBM serum alone did 
not result in elevated BUN (Fig. 1 A), despite the localization 
of the heterologous anti-GBM antibodies to the glomeruli 
(Fig. 1 C). Renal pathology was dependent, therefore, on the 
presence of mouse anti–sheep antibodies which colocalized to 
the glomeruli in the CFA + NTS–treated animals (Fig. 1 C) 
in a “ribbon” pattern, characteristic of Goodpasture’s Disease, 
and was completely dependent on FcR expression. Mice de-
fi  cient in the common γ chain, hence defi  cient in surface 
expression of the activation Fc receptors FcγRI, III and IV, 
as well as FcεRI, were protected from the pathogenic conse-
quences of CFA + NTS (Fig. 1 B).
IgG2b anti–sheep Ig is dominantly induced in the CFA + NTS 
model of nephrotoxic nephritis
Individual, γ chain–dependent FcRs interact with specifi  c 
isotypes and subclasses of immunoglobulins (13, 14). To fur-
ther defi   ne the pathology observed in the CFA + NTS 
model, wild-type mice were characterized for the specifi  c 
subclasses of IgG anti–sheep GBM antibodies they produced 
at day 4 after CFA + NTS treatment. As shown in Fig. 2, 
Figure 1.  Renal disease in presensitized, NTS-treated mice is FcR 
dependent. (A) Serum samples were collected from fi  ve C57BL/6 mice in 
each group on day 8 after anti-GBM antiserum (NTS) administration 
alone (NTS alone) or with sheep IgG and CFA preimmunization 4 d before 
(CFA + NTS), or preimmunization alone (CFA alone). CFA + NTS treat-
ment was necessary for the induction of nephritis. The dagger indicates 
mice that died before day 8. (B) Serum samples were collected on day 8 
after NTS administration from 5 C57BL/6 mice or FcRγ−/− mice preim-
munized with sheep IgG and CFA. Renal pathology was dependent on 
FcR. (C) Deposition of sheep anti-GBM antibody, autologous mouse anti–
sheep IgG antibody, and complement C3 along the GBM. C57BL/6 mice 
were injected with NTS alone or with sheep IgG and CFA preimmuniza-
tion (CFA + NTS), and kidneys were removed on day 4 (Bar, 200 μm). 
Autologous mouse IgG deposition was essential for the induction of 
nephritis in CFA + NTS treated mice. Data shown are representative of 
three independent experiments.JEM VOL. 203, March 20, 2006  791
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only mouse IgG2b anti–sheep Ig showed a statistically signifi  -
cant elevation (P < 0.001) after CFA + NTS treatment. 
NTS alone did not induce measurable levels of mouse anti–
sheep Ig at day 4 after exposure to anti-GBM serum. IgG1 
anti–sheep Ig was elevated, although the level was not statis-
tically signifi  cant over baseline or NTS alone (Fig. 2).
The renal pathology induced by mouse IgG2b 
is Fc𝗄RIV dependent
We recently described a novel IgG Fc receptor in the mouse 
with selective specifi  city for IgG2a and 2b and with a binding 
affi   nity  10-fold higher than that observed for these subclasses 
binding to FcγRIII (13). To determine the relative contribu-
tions of these Fc receptors to the renal pathology observed in 
the nephrotoxic nephritis model described here, we induced 
disease in either common γ chain–defi  cient (FcRγ−/−), 
FcγRIII–defi  cient (FcγRIII−/−) or wild-type mice treated 
with a monoclonal anti-FcγRIV antibody shown to specifi  -
cally block this activation FcγR (13, 14; Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20051900/DC1). 
Common γ chain–defi  cient mice were protected, as ex-
pected, as were mice treated with the anti-FcγRIV block-
ing mAb (Fig. 3, A and B, and Fig. S2). FcγRIII-defi  cient 
mice developed disease comparable with wild-type mice, 
whereas FcγRIIB-defi   cient mice displayed enhanced dis-
ease, as revealed by the accelerated mortality of this strain 
when treated with CFA + NTS (Fig. 3 B). We also induced 
nephrotoxic nephritis in FcγRI and RIII double–defi  cient 
(FcγRI/III−/−) mice, and these animals developed disease 
comparable with wild-type controls (Fig. 3, C and D and 
Fig. S2). Because no diff  erences in the titer of mouse IgG2b 
anti–sheep Ig was observed for any of the genotypes studied 
(Fig. S3), the data indicate that the critical activation FcγR 
in this model is FcγRIV, which is consistent with studies 
in passive models of idiopathic thrombocytopenic purpura 
(ITP) and B cell and tumor cell clearance (13, 14; unpub-
lished data). Staining of infi  ltrating macrophages with anti-
FcγRIV antibody revealed accumulation of these cells in the 
Figure 3.  Nephrotoxic nephritis is exclusively Fc𝗄RIV dependent. 
(A) Serum samples were collected on day 8 after NTS administration from 
fi  ve individual FcRγ−/−, FcγRIII−/−, FcγRIIB−/−, or wild-type mice treated 
with anti-FcγRIV antibody or its isotype control antibody. The dagger 
indicates mice that died before day 8. NTS nephritis was FcγRIII indepen-
dent, whereas it was FcγRIV dependent. Signifi  cance of the results was 
determined by Student’s t test. (B) Kaplan-Meier analysis of survival rate 
of FcγRIII−/−, FcγRIIB−/−, or wild-type mice treated with anti-FcγRIV 
antibody or its isotype control antibody (n = 5). Treatment with anti-
FcγRIV antibody showed protection in wild-type NTS nephritis mice. The 
log rank test was used to determine signifi  cance between mouse groups 
treated with anti-FcγRIV antibody or treated with its isotype control anti-
body. (C) Serum samples were collected on day 8 after NTS administration 
from six individual FcγRI/III−/− or control mice. The dagger indicates mice 
that died before day 8. NTS nephritis was both FcγRI and FcγRIII indepen-
dent. (D) Kaplan-Meier analysis of the survival rate of FcγRI/III−/− or con-
trol mice (n = 6). There was no signifi  cant difference in survival rate. 
(E) Immunohistochemical staining for FcγRIV on kidney section of wild-
type mice on day 4 after NTS administration alone or with sheep IgG and 
CFA preimmunization (CFA + NTS). The arrow highlights an FcγRIV-
  positive cell infi  ltrating in the diseased glomerulus (brown). Data shown 
are representative of three independent experiments.
Figure 2.  IgG subclass-restricted production of mouse anti–sheep 
IgG antibody in presensitized, NTS-treated mice. Serum titer of each 
isotype of anti–sheep IgG-specifi  c IgG in C57BL/6 mice was measured by 
ELISA on day 4 after NTS injection alone or with sheep IgG and CFA pre-
immunization (CFA + NTS). Only mouse IgG2b anti–sheep IgG in mice 
treated with CFA + NTS showed statistically signifi  cant elevation com-
pared with baseline level or with sera from mice treated with NTS alone. 
Signifi  cance was determined by Student’s t test. Data shown are repre-
sentative of three independent experiments.792  NEPHROTOXIC NEPHRITIS IS FCγRIV DEPENDENT | Kaneko et al.
glomeruli of CFA + NTS–treated animals, thus providing a 
mechanism for their engagement of IgG2b immune complex 
deposited on the GBM and the infl  ammation observed in this 
model (Fig. 3 E).
Modulation of FcRs by IVIG attenuates disease 
in nephrotoxic nephritis
We have previously demonstrated in passive models of ITP 
and arthritis that IVIG is able to protect from the pathogenic 
consequences of cytotoxic antibodies or immune complex 
deposition by induction of the inhibitory receptor, FcγRIIB 
(18, 19). Similarly, IVIG treatment attenuates the renal pa-
thology observed in CFA + NTS nephrotoxic nephritis and 
is dependent on the Fc fragment for its activity (Fig. 4 A). 
This protection results in extended survival for IVIG-
treated animals (Fig. 4 B). IVIG treatment did not modify 
the development of mouse IgG2b anti–sheep Ig antibodies 
(Fig. S3) or the deposition of either sheep anti-GBM anti-
bodies, total mouse IgG or IgG2b antibodies, or complement 
C3 in the glomeruli (Fig. 5). To determine the mechanism 
Figure 5.  Histopathology and deposition along the GBM of kidney 
section in NTS nephritis mice with or without IVIG treatment. 
(A) PAS staining of kidney section on day 8 from NTS nephritis mice 
treated with either 10% maltose (vehicle) alone or IVIG. Vehicle alone 
shows severe tissue damage with intracapillary cellular proliferation, 
  glomerular thrombosis, and mesangiolysis. In contrast, renal pathology 
of NTS mice treated with IVIG was markedly attenuated. Kidney sections 
from mouse groups on day 4 were equally stained with FITC-conjugated 
anti–sheep IgG antibody, Cy3-conjugated anti–mouse IgG antibody, FITC-
conjugated anti–mouse IgG2b antibody, and FITC-conjugated anti–mouse 
complement 3 antibody (Bar, 200 μm). (B) Quantitative immunofl  uores-
cence of glomerular deposits of sheep IgG, mouse IgG, mouse IgG2b, and 
mouse C3 on day 4. There was no signifi  cant difference between the 
groups. Data shown are representative of three independent experiments.
Figure 4.  IVIG protects mice from nephrotoxic nephritis. (A) Six 
C57BL/6 mice in each group were injected with IVIG (1 g/kg), IVIG-Fc por-
tion (0.33 g/kg), IVIG-Fab portion (0.67 g/kg), or 10% maltose (vehicle of 
IVIG) 1 h before NTS administration. Serum samples were collected on day 
8 after NTS administration. 1 g/kg of mouse weight of IVIG and equimolar 
concentrations of IVIG–Fc portion showed the same protective effect in 
NTS nephritis mice. The dagger indicates mice that died before day 8. 
(B) Kaplan-Meier analysis of survival rate in NTS nephritis mice treated 
with IVIG or its vehicle alone (n = 10). IVIG treatment improved survival 
rate of NTS mice. Signifi  cance of differences was verifi  ed by log rank test. 
Data shown are representative of three independent experiments.JEM VOL. 203, March 20, 2006  793
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by which IVIG protects CFA + NTS–treated mice from 
developing renal pathology, we examined the expression of 
FcγRIIB and FcγRIV on macrophages infi  ltrating the kid-
ney in this disease. As shown in Fig. 6 A, IVIG signifi  cantly 
induces the surface expression of FcγRIIB on infi  ltrating 
macrophages (P = 0.004), as we have previously described 
for splenic (18) and infi   ltrating synovial macrophages 
(19). However, and in contrast to these previous studies, 
IVIG treatment also resulted in reduced surface expression 
of FcγRIV (Fig. 6 B and Fig. S4, available at http://www.
jem.org/cgi/content/full/jem.20051900/DC1). FcγRIII ex-
pression was unchanged (unpublished data) as was FcγRIIB 
and FcγRIV expression on granulocytes (unpublished data). 
The combined eff   ect of reduced FcγRIV and elevated 
FcγRIIB alters the activation threshold for IgG2b engage-
ment of FcγRIV and protects mice from the pathologi-
cal consequences of IgG2b immune complex deposition in 
the glomeruli.
Fc𝗄RIIB up-regulation by IVIG is required to protect mice 
from NTS + CFA induced nephrotoxic nephritis
Because IgG2b can bind to both FcγRIII and FcγRIV, 
  albeit with signifi  cantly diff  erent affi   nities, the relative con-
tributions of FcγRIIB, FcγRIII and FcγRIV modulation 
to the protective eff  ect of IVIG was examined. As we have 
observed previously (18, 19), IVIG protection was ablated 
in FcγRIIB-defi  cient mice (Fig. 7 and Fig. S5, available at 
http://www.jem.org/cgi/content/full/jem.20051900/DC1), 
which is consistent with FcγRIIB expression contribut-
ing to the protective eff  ect of IVIG. Thus, the down-regu-
lation of FcγRIV by IVIG treatment was not suffi   cient to 
provide protection, and thus required additional modulation 
of FcγRIIB. CFA + NTS–treated FcγRIIB-defi  cient mice 
were protected by anti-FcγRIV, indicating that FcγRIV is 
the sole activation FcR involved in the pathology of this dis-
ease, despite the ability of IgG2b to engage FcγRIII. Consis-
tent with this observation, IVIG protection was not aff  ected 
by FcγRIII defi  ciency (Fig. 7).
DISCUSSION
The selective engagement of IgG subclasses with specifi  c 
FcγRs is a determining factor in the pathophysiology of a 
variety of antibody-mediated infl   ammatory disorders and 
antibody based immunotherapeutics. Simultaneous engage-
ment of both activating (FcγRIII and FcγRIV in the mouse 
model; FcγRIIA and FcγRIIIA in the human model) and 
inhibitory receptors (FcγRIIB in both mouse and human 
models) determines the threshold for triggering activation 
of eff  ector cells such as macrophages, mast cells, and neu-
trophils. Detailed studies performed in the murine system 
have revealed the specifi  cs of these interactions. Thus, IgG1 
antibodies mediate their in vivo activity through simultane-
ous engagement of the low-affi   nity receptors FcγRIIB and 
FcγRIII, whereas IgG2a and IgG2b are dependent on the 
FcγRIIB and FcγRIV pair. Several studies have confi  rmed 
the role of FcγRIIB and FcγRIII in IgG1-mediated infl  am-
mation in vivo, based on studies performed in experimental 
models of cytotoxic antibody–triggered clearance including 
ITP (13), hemolytic anemia (27, 28) B cell clearance (29) and 
tumor metastases (9); and immune complex–mediated dis-
eases, such and the cutaneous and alveolar Arthus reactions 
(30) and KRNxNOD serum-induced arthritis (19). Passive 
models of IgG2a- and 2b-mediated clearance, although sen-
sitive to deletion of the common γ chain and hence defi  cient 
in FcγRI, III and RIV, were not sensitive to either FcγRI 
or RIII deletion (13, 14). Instead, blockade of FcγRIV ab-
rogates IgG2a- or 2b-mediated eff  ector responses in vivo in 
passive models of ITP, B cell clearance; and tumor metas-
tasis (13, 14; unpublished data). Thus, despite the ability of 
IgG2a to bind with high affi   nity to the activating receptor 
FcγRI (31), this receptor has not been shown to be central 
to the mechanism by which IgG2a mediates its biological 
activity in vivo (28, 32). This general lack of FcγRI involve-
ment is likely to result from the occupancy of this recep-
tor by circulating  immunoglobulin during the steady state, 
thereby rendering it unavailable for specifi  c IgG2a-mediated 
cross-linking.
Several active models of antibody-mediated infl  ammation 
have suggested that skewing of the IgG subclass response oc-
curs in response to a variety of infl  ammatory stimuli. Thus, in 
spontaneous murine lupus models, anti-DNA antibodies of 
the IgG2a or 2b class appear to dominate (unpublished data). 
Similarly, active antiviral protection models have observed 
Figure 6.  Up-regulation of Fc𝗄RIIB and down-regulation of 
Fc𝗄RIV by IVIG on F4/80-positive cells infi  ltrating in the kidney. 
Leukocytes infi  ltrating in the kidney of NTS nephritis mice treated with 
IVIG or its vehicle (10% maltose) were isolated on day 2 after NTS admin-
istration, and mean fl  uorescent intensities of FcγRIIB (A) and FcγRIV (B) 
on F4/80-positive cells were evaluated by fl  ow cytometry using the FcγR-
specifi  c antibody Ly 17.2 (reference 17) and 9G8.1 (reference 13). F4/80-
positive cells in the kidney of NTS mice treated with IVIG showed 
signifi  cant up-regulation of FcγRIIB and down-regulation of FcγRIV 
 expression.  Signifi  cance was verifi  ed by Student’s t test. Data shown 
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a dominant role for IgG2a antiviral antibodies (33–35). Our 
present study reveals that skewing to IgG2b is prominent in 
accelerated anti-GBM nephritis, perhaps as a result of the 
contribution of TGFβ to the glomerular injury seen in this 
model (36). TGFβ up-regulation has been shown to occur 
in a variety of conditions of renal injury (37, 38) and has 
also been shown to induce class switching to IgG2b in vitro 
(39, 40). It is likely that skewing of IgG subclasses will be a 
common feature of infl  ammatory conditions, in response to 
the specifi  c cytokine milieu present in these states. Although 
previous studies of accelerated nephrotoxic nephritis all dem-
onstrated a dependence on FcγRs by virtue of the protec-
tion observed in the common γ chain–defi  cient strain, these 
studies diff  ered on the role of FcγRIII in this model. Fujii 
et al. (41) demonstrated that renal disease was substantially 
attenuated in a rabbit anti-GBM model in FcγRIII-defi  cient 
mice, although to a lesser degree than FcRγ chain defi  ciency 
for some parameters of renal injury. These investigators did 
not defi  ne the IgG subclasses involved in their model, which 
could account for the diff  erences with our study. It is tempt-
ing to speculate that the mouse anti–rabbit GBM antibody 
response is dominated by IgG1 antibodies, hence FcγRIII 
dependent, in contrast to the mouse anti–sheep GBM anti-
body response that is IgG2b and FcγRIV dependent. Tarzi 
et al. (42), using a sheep anti-GBM model of nephrotoxic 
nephritis, similar to that used in this study, observed pro-
tection in FcRγ-defi  cient mice, but not FcγRIII-defi  cient 
animals, similar to our observations. They did not investi-
gate FcγRI-defi  cient mice, but did report attenuation in the 
double FcγRI/III-defi  cient strain. They, however, used a 
fi  vefold lower dose of sheep GBM antiserum in their experi-
ments and mainly histological changes as readout. Moreover, 
the specifi  c IgG subclasses were not described. In contrast, 
we observe severe BUN elevation and almost 50% mortality 
under our experimental conditions.
Consistent with our previous studies (18, 19), we demon-
strate that high dose intravenous IgG protects mice from 
nephrotoxic nephritis and this protection is dependent on 
FcγRIIB. FcγRIIB-defi   cient mice are not protected by 
IVIG, because one activity of IVIG is to up-regulate FcγRIIB 
on infi  ltrating macrophages. This mechanism has also been 
observed in the serum transfer arthritis model, KRNxNOD 
(19), which is an IgG1-mediated immune complex–driven 
model of arthritis and results in an elevated threshold for 
FcγRIII-driven infl  ammation. However, in contrast to that 
FcγRIII-driven model, the eff  ect of IVIG in this study is to 
both up-regulate FcγRIIB and down-regulate FcγRIV. 
  Because IgG2b has an activation/inhibitory affi   nity ratio 70 
times that of IgG1, resulting from the higher affi   nity of IgG2b 
for FcγRIV (13), up-regulation of FcγRIIB alone would 
not be suffi   cient to raise the threshold required to prevent 
macrophage triggering by IgG2b immune complexes. Thus, 
the mechanism of protection by IVIG diff  ers for IgG sub-
classes and suggests that the normal physiological mechanism 
underlying this activity refl  ects an in vivo feedback inhibition 
pathway that is subclass specifi  c and has evolved to prevent 
Figure 7.  IVIG protection in nephrotoxic nephritis requires 
Fc RIIB. (A) Serum samples were collected on day 8 after administration 
of NTS from wild-type (WT), FcγRIIB−/−, or FcγRIII−/− presensitized mice 
treated with IVIG or its vehicle (10% maltose) alone (n = 10). Addition-
ally, four FcγRIIB−/− mice in each group were treated with anti-FcγRIV 
antibody or its isotype control antibody. The dagger indicates mice that 
died before day 8. IVIG was protective in wild-type and FcγRIII−/− NTS 
nephritis mice, but not in FcγRIIB−/− mice. Anti-FcγRIV antibody treat-
ment in FcγRIIB−/− mice showed the same effect as IVIG on wild-type 
or FcγRIII−/− mice. Signifi  cance was verifi  ed by Student’s t test. (B) PAS 
staining of kidney section on day 8 from NTS nephritis. FcγRIIB−/− mice 
treated with IVIG or its vehicle alone showed equally severe tissue dam-
age with intracapillary cellular proliferation, glomerular thrombosis, and 
mesangiolysis. (C) Kaplan-Meier analysis of survival rate of FcγRIII−/− 
and FcγRIIB−/− mice treated with IVIG or its vehicle alone (n = 10). 
Survival rate was signifi  cantly improved by IVIG treatment in FcγRIII−/− 
mice, but not in FcγRIIB−/− mice. Signifi  cance was determined 
by log rank test.JEM VOL. 203, March 20, 2006  795
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sustained and inappropriate eff  ector cell activation after reso-
lution of an infl  ammatory state.
Our present study highlights the importance of specifi  c 
IgG subclasses and their cognate Fc receptors in defi  ning the 
pathophysiology of disease states. This knowledge is of im-
portance in identifying the molecular pathways involved and 
thereby selecting the appropriate targets for intervention.
MATERIALS AND METHODS
Mice. C57BL/6 mice were purchased from the Jackson Laboratory. 
FcRγ−/− (2), FcγRIIB−/− (8), and FcγRIII−/− mice were generated in our 
laboratory and backcrossed for 12 generations to the C57BL/6 background. 
FcγRI/III−/− mice on a hybrid C57BL/6/129F2 background were com-
pared with a genetically matched control line. Female mice at 6–10 wk of 
age were used for all experiments and maintained at the Rockefeller Univer-
sity animal facility. All experiments were done in compliance with fed-
eral laws and institutional guidelines and have been approved by the 
Rockefeller University.
Antibodies and transfectants. Human IVIG (5% in 10% maltose, chro-
matography purifi  ed) was purchased from Octapharma. Digestion of human 
IVIG was performed as described previously (19). In brief, IVIG was di-
gested by 0.5 mg/ml papain for 1 h at 37°C, and stopped by the addition of 
2.5 mg/ml iodocasetamide. The resulting Fab and Fc fragments were sepa-
rated from nondigested IVIG on a HiPrep 26/60 S-200HR column (GE 
Healthcare), and then Fc fragments were separated from Fab fragments using 
a protein G column (GE Healthcare) and a protein L column (Pierce Chem-
ical Co.). Fragment purity was checked by immunoblotting using anti–
  human IgG Fab- or Fc-specifi   c antibodies (Jackson ImmunoResearch 
Laboratories). Purity was judged to be >99%. Antibodies 2.4G2, Mac-1, 
Gr-1 were purchased from BD Biosciences. The anti-FLAG antibody was 
purchased from Sigma-Aldrich. The F4/80 and CD68 antibody was ob-
tained from Serotec. The Ly 17.2 antibody was purchased from Caltag. 
Hamster monoclonal antibodies against mouse FcγRIV, 9E9, and 9G8.1 
were generated in our laboratory (13). 200 μg of the 9E9 antibody, which 
interferes with immune complex binding to FcγRIV, was injected intrave-
nously every other day from day 0 to 14. Hamster IgG was used as an isotype 
control. The 9G8.1 antibody was conjugated with Alexa 647 (Invitrogen) 
and used for fl  ow cytometric analysis. Chinese hamster ovary cells stably 
transfected with FLAG-tagged murine versions of FcγRI, FcγRIIB, FcγRIII, 
and FcγRIV were generated in our laboratory (13).
Preparation of sheep NTS. Sheep anti-GBM antigen was prepared as de-
scribed previously (43). In brief, glomeruli were isolated from normal 
C57BL/6 mouse kidneys by diff  erential sieving, washed extensively, and 
used to hyperimmunize sheep as described previously (43). The hyperim-
mune serum was heat inactivated, and then absorbed with excess amount of 
murine red blood cells.
Induction of anti-GBM glomerulonephritis. Mice were preimmunized 
intraperitoneally with 200 μg of sheep IgG (Serotec) in CFA, followed by 
intravenous injection of sheep NTS (2.5 μl of serum per gram of mouse) 
4 d later. IVIG (1 g/kg) or its vehicle alone was injected 1 h before anti-
GBM antiserum injection.
Histological analysis. Kidneys were removed, fi  xed in 10% buff  ered for-
malin, and embedded in paraffi   n. 4 μm paraffi   n sections were stained with 
periodic acid-Schiff   (PAS) and evaluated by light microscopy in a blind man-
ner as previously described (44). In brief, the clinical scores of glomerular in-
jury were graded into fi  ve grades: 0 (normal), 1 (mild increase in cellularity), 
2 (defi  nite glomerular enlargement, focal hypercellularity and mild increase 
of matrix), 3 (focal hypercellularity and proliferation in >50% of glomeruli), 
and 4 (diff  use proliferative change with crescents and sclerosis in >50% of 
glomeruli). Tubulointerstitial lesions were also graded from 0 to 4 according 
to the severity of infl   ammatory cell infi  ltration. Crescent formation was 
evaluated as the number of the crescents per 10 glomeruli. The mean num-
ber of macrophages infi  ltrating in the glomeruli were counted in 50 glomer-
uli in each sample.
Immunofl  uorescence and immunohistochemical staining. 4-μm fro-
zen sections were fi  xed in acetone and stained with FITC-conjugated anti–
sheep IgG, Cy3-conjugated anti–mouse IgG (Jackson ImmunoResearch), 
FITC-conjugated anti–mouse C3 (Cedarlane), and FITC-conjugated anti–
mouse IgG2b (BD Biosciences) antibody, respectively. For quantitative im-
munofl  uorescence, blinded sections were examined at 100 magnifi  cation 
using MetaMorph version 6.1 (Molecular Devices). The mean intensity of 
20 glomeruli for each sample was measured for evaluation. For immunohis-
tochemical analysis, frozen sections were incubated with 5 μg/ml of biotin-
ylated anti-FcγRIV monoclonal antibody (clone 9E9) after blocking with 
500 μg/ml of hamster IgG in 5% goat serum and biotin blocking (Dako-
Cytomation). After blocking of endogenous peroxidase was performed, 
HRP-conjugated rabbit antibiotin antibody ( DakoCytomation) was 
used as the secondary antibody and 3–3′-diaminobenzidine was used for 
  visualization. Biotinylated anti-CD68 antibody (clone FA11) was used to 
detect macrophages in the kidney.
Measurement of sheep IgG-specifi  c circulating IgG levels. 96-well 
ELISA plates coated with 5 μg/ml of sheep IgG were incubated with 1:500 
diluted test sera after blocking with 5% bovine serum albumin. After washing 
with PBS containing 0.05% Tween 20, the plates were incubated with 
HRP-conjugated anti–mouse IgG1, IgG2c (Igh 1b allele of IgG2a), IgG2b, 
or IgG3 antibody (Bethyl Laboratories). For the color development, 
3,3′,5,5′-tetramethylbenzidine was used.
Measurement of blood urea nitrogen. BUN in sera was measured by 
the urease–indophenol method with an Enzymatic Urea Nitrogen kit 
  (Stambio Laboratory).
Preparation of kidney-infi  ltrating cells and fl  ow cytometric analysis. 
Kidneys were pressed through a mesh, and the cells were resuspended in 
PBS. After washing, the cells were suspended in 33% Percoll solution 
and centrifuged 2,000 rpm for 20 min at room temperature. After red blood 
cell lysis, the cells were stained with the indicated monoclonal antibodies, 
and were subjected to fl  ow cytometric analysis. 2,000 F4/80-positive cells 
infi  ltrating in the kidneys of each mouse were evaluated for mean fl  uores-
cence intensity of FITC-conjugated Ly 17.2 or Alexa 647–conjugated 
9G8.1 antibody.
Statistical analysis. Statistical diff  erences in each group for the BUN, cir-
culating IgG levels, and mean fl  uorescent intensity, were calculated with 
Student’s t test. Mann-Whitney U test was used for histological analysis. 
Survival rate was analyzed with Kaplan-Meier estimates, and groups were 
compared with the log rank test. P < 0.05 was considered signifi  cant. SPSS 
version 11.0 for Windows (SPSS Inc.) was used for statistical analysis.
Online supplemental material. Fig. S1 shows specifi  city of anti-FcγRIV 
monoclonal antibody 9E9. Fig. S2 demonstrates histological evaluation 
of kidney sections from wild-type C57BL/6 mice, anti-FcγRIV anti-
body–treated or isotype-matched antibody–treated wild-type C57BL/6 
mice, FcγRI/III−/− mice or its genetically matched control (129/B6) 
mice on day 8 from NTS injection. Fig. S3 contains serum titer of 
each isotype of autologous mouse anti–sheep IgG-specifi  c IgG. Fig. S4 
shows histograms of FcγRIIB and FcγRIV expression on F4/80-posi-
tive cells infi  ltrating the kidney on day 2. Fig. S5 demonstrates histo-
logical evaluation of kidney sections from wild-type C57BL/6 mice 
and FcγRIIB−/− mice treated with IVIG or its vehicle on day 8 from 
NTS injection. Supplemental fi  gures are available at http://www.jem.
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